FENNEC PHARMACEUTICALS ($FENC) posted quarterly earnings results for Q2 2026 on Tuesday, August 11th. The company reported earnings of $0.05 per share, beating estimates of $0.01 by $0.04. The company also reported revenue of $17,870,000, beating estimates of $16,440,696 by $1,429,304.
You can see Quiver Quantitative's $FENC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FENNEC PHARMACEUTICALS Insider Trading Activity
FENNEC PHARMACEUTICALS insiders have traded $FENC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FENC stock by insiders over the last 6 months:
- ROSTY RAYKOV sold 10,781 shares for an estimated $69,753
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
FENNEC PHARMACEUTICALS Hedge Fund Activity
We have seen 54 institutional investors add shares of FENNEC PHARMACEUTICALS stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC added 504,537 shares (+25.5%) to their portfolio in Q2 2026, for an estimated $5,423,772
- BLACKROCK, INC. added 358,893 shares (+26.2%) to their portfolio in Q2 2026, for an estimated $3,858,099
- ROSALIND ADVISORS, INC. added 294,693 shares (+11.3%) to their portfolio in Q1 2026, for an estimated $1,812,361
- APIS CAPITAL ADVISORS, LLC removed 204,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,254,600
- POTOMAC CAPITAL MANAGEMENT, INC. added 129,300 shares (+136.0%) to their portfolio in Q1 2026, for an estimated $795,195
- MARSHALL WACE, LLP removed 127,693 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $785,311
- SOLAS CAPITAL MANAGEMENT, LLC removed 78,528 shares (-3.1%) from their portfolio in Q1 2026, for an estimated $482,947
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
FENNEC PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $FENC recently. We have seen 2 analysts offer price targets for $FENC in the last 6 months, with a median target of $14.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $16.0 on 05/22/2026
- David Nierengarten from Wedbush set a target price of $13.0 on 04/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
